Does TIRAGOLUMAB Cause Malignant neoplasm progression? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Malignant neoplasm progression have been filed in association with TIRAGOLUMAB. This represents 1.4% of all adverse event reports for TIRAGOLUMAB.
8
Reports of Malignant neoplasm progression with TIRAGOLUMAB
1.4%
of all TIRAGOLUMAB reports
8
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TIRAGOLUMAB?
Of the 8 reports, 8 (100.0%) resulted in death, 2 (25.0%) required hospitalization, and 1 (12.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TIRAGOLUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does TIRAGOLUMAB Cause?
Off label use (58)
Hyperthyroidism (39)
Pneumonia (29)
Pneumonitis (26)
Infusion related reaction (23)
Intentional product use issue (23)
Death (21)
Adrenal insufficiency (20)
Troponin increased (20)
Colitis (15)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TIRAGOLUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
TIRAGOLUMAB vs TIRBANIBULIN
TIRAGOLUMAB vs TIRZEPATIDE
TIRAGOLUMAB vs TISLELIZUMAB
TIRAGOLUMAB vs TISOTUMAB VEDOTIN
TIRAGOLUMAB vs TISOTUMAB VEDOTIN-TFTV